Humanized SCID mice models of SLE

Current Pharmaceutical Design

Volumn 17, Issue 13, 2011, Pages 1261-1266

  Kerekov, Nikola ^a   Mihaylova, Nikolina ^a   Prechl, Jozsef ^b   Tchorbanov, Andrey ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Chimeric molecules; Inhibitory B cell receptors; SCID models of SLE

Indexed keywords

B LYMPHOCYTE RECEPTOR; COMPLEMENT RECEPTOR; MONOCLONAL ANTIBODY;

ANTIGENICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL TRANSFER; CHIMERA; CROSS LINKING; EXPERIMENTAL MOUSE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCID MOUSE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 79958078993     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795703780     Document Type: Article

References (69)

1. Lahita RG. The influence of sex hormones on the disease systemic lupus erythematosus. Springer Semin Immunopathol 1986; 9(2-3): p. 305-14.
2. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. The role of B cells in lpr/lpr-induced autoimmunity J Exp Med 1994; 180: 1295-306.
3. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-48.
4. Dorner T. Therapy: Hydroxychloroquine in SLE: old drug, new perspectives. Nat Rev Rheumatol 2010; 6(1): p. 10-1.
5. Toubi E, Rosner I, Rozenbaum M, Kessel A, Golan TD, The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9(2): p. 92-5.
6. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003; 15(5): p. 528-34.
7. Klippel JH. Indications for, and use of, cytotoxic agents in SLE. Baillieres Clin Rheumatol 1998; 12(3): p. 511-27.
8. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-90.
9. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56: 3044-56.
10. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol 2005; 117: 207-13.
11. Looney RJ, Anolik J, Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004; 13: 381-90.
12. Dörner T, Kaufmann J, Wegener W, Teoh N, Goldenberg D, Burmester G. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Research & Therapy 2006; (R74).
13. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48(11): p. 3253-65.
14. Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006; 91(2): p. 586-99.
15. Auyeung-Kim, DJ, Devalaraja MN, Migone TS, Cai W, Chellman GJ. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod Toxicol 2009; 28(4): p. 443-55.
16. Kalsi JK, Martin AC, Hirabayashi Y, et al. Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Mol Immunol 1996; 33: 471-83.
17. Hahn BH. Antibodies to DNA. NEJM 1998; 19: 1359-68.
18. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-48.
19. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 147-53.
20. Odendahl M, Jacobi A, Hansen A, Feist E, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165(10): p. 5970-9.
21. Jacobi AM, Odendahl M, Reiter K, Bruns A, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48(5): p. 1332-42.
22. Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, et al. HLADRhigh/ CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69(1): p. 305-8.
23. Schultz KR, Klarnet JP, Gieni RS, HayGlass KT, Greenberg PD. The role of B cells for in vivo T cell responses to a Friend virusinduced leukemia. Science 1990; 249(4971): p. 921-3.
24. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008; 8(5): p. 391-7.
25. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184(4): p. 1397-411.
26. Schultze JL, Michalak S, Lowne J, Wong A, et al. Human nongerminal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses. J Exp Med 1999; 189(1): p. 1-12.
27. Kindler V, Matthes T, Jeannin P, Zubler RH. Interleukin-2 secretion by human B lymphocytes occurs as a late event and requires additional stimulation after CD40 cross-linking. Eur J Immunol 1995; 25(5): p. 1239-43.
28. Halverson R, Torres RM, Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat Immunol 2004; 5(6): p. 645-50.
29. Nemazee D. Does immunological tolerance explain the waste in the B-lymphocyte immune system? Experiment and theory. Ann N Y Acad Sci 1995; 764: p. 397-401.
30. Wang YH, Diamond B. B cell receptor revision diminishes the autoreactive B cell response after antigen activation in mice. J Clin Invest 2008; 118: 2896-907.
31. Long EO. Regulation of immune responses trough inhibitory receptors. Ann Rev Immunol 1999; 17: 875.
32. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000; 290: 84-89.
33. Tarasenko T, Dean JA, Boland S. FcγRIIb as a modulator of autoimmune disease susceptibility. Autoimmunity 2007; 40(6): 409-17.
34. Jozsi M, Prechl J, Bajtay Z, Erdei A. Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J Immunol 2002; 168: 2782-8.
35. Wagner C, Ochmann C, Schoels M, et al. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Mol Immunol 2006; 43: 643-51.
36. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry M, Shlomchik M. Depletion of B cells in Murine lupus: Efficacy and resistance. J Immunol 2007; 179: 3351-61.
37. Lund F. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008; 20: 332-8.
38. Bouaziz JD, Yanada K, Venturi GM, et al. Therapeutic B cell depletion impaires adaptive and autoreactive CD4+ T cell activation in mice. PNAS 2007; 104: 20878-83.
39. Daëron M, Lesourne R. Negative Signaling in Fc Receptor Complexes. Adv Immunol 2006; 89: 39-86.
40. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19-28.
41. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006; 203: 789-97.
42. Tchorbanov A, Voynova E, Mihaylova N, et al. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur J Immunol 2007; 37: 3587-96.
43. Hoyer BF, Moser K, Hauser AE, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004; 199: 1577-84.
44. Mihaylova N, Voynova E, Tchorbanov A, Nikolova M, et al. Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor. Int Immunol 2008; 20(2): p. 165-75.
45. Terstappen LW, Johnsen S, Segers-Nolten IM, Loken MR. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990; 76(9): p. 1739-47.
46. Iking-Konert C, Stocks S, Weinsberg F. First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104. Ann Rheum Dis 2004; 63: 1104-12.
47. Putterman C, Deocharan B, Diamond B. Molecular analysis of the autoantibody response in peptide-induced autoimmunity. J Immunol 2000; 164: 2542-9.
48. Voynova E, Tchorbanov A, Prechl J, et al. An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B lymphocytes. Imm Let 2008; 116: 168-73.
49. Steinberg AD, Raveche ES, Laskin CA, Smith HR, et al. NIH conference. Systemic lupus erythematosus: insights from animal models. Ann Intern Med 1984; 100(5): p. 714-27.
50. Mountz, J. D, W.C. Gause, R. Jonsson, Murine models for systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 1991; 3(5): p. 738-56.
51. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: p. 269-390.
52. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: p. 243-69.
53. Izui S, Ibnou-Zekri N, Fossati-Jimack L, Iwamoto M. Lessons from BXSB and related mouse models. Int Rev Immunol 2000; 19(4-5): p. 447-72.
54. Merino R, Fossati L, Izui S. The lupus-prone BXSB strain: the Yaa gene model of systemic lupus erythematosus. Springer Semin Immunopathol 1992; 14(2): p. 141-57.
55. Furukawa F, Yoshimasu T. Animal models of spontaneous and drug-induced cutaneous lupus erythematosus. Autoimmun Rev 2005; 4(6): p. 345-50.
56. Furukawa F, Tanaka H, Sekita K, Nakamura T, Horiguchi Y, Hamashima Y. Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res 1984; 276(3): p. 186-94.
57. Hang L, Theofilopoulos AN, Dixon FJ. A spontaneous rheumatoid arthritis-like disease in MRL/l mice. J Exp Med 1982; 155(6): p. 1690-701.
58. Koopman WJ, Gay S. The MRL-lpr/lpr mouse. A model for the study of rheumatoid arthritis. Scand J Rheumatol Suppl 1988; 75: p. 284-9.
59. Voynova EN, Tchorbanov AI, Todorov TA, Vassilev TL. Breaking of tolerance to native DNA in nonautoimmune mice by immunization with natural protein/DNA complexes. Lupus 2005; 14(7): 543-50.
60. Quddus J, Johnson KJ, Gavalchin J, Amento EP, et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 1993; 92(1): p. 38-53.
61. Yung, R, Chang S, Hemati N, Johnson K, Richardson B. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 1997; 40(8): p. 1436-43.
62. Yung R, Powers D, Johnson K, Amento E, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97(12): p. 2866-71.
63. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am 1994; 20(1): p. 61-86.
64. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009; 30(9): p. 455-64.
65. Dimitrova I, Gesheva V, Nikolova K, Mihaylova N, et al. Target silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity. Lupus 2010; 19(11): p. 1261-71.
66. Artinian B, Reesal M. Procainamide-induced SLE and lymphoreticular disorders. Can Med Assoc J 1974; 110(3): p. 314 passim.
67. Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 2004; 137(3): p. 513-20.
68. Sthoeger Z, Zinger H, Dekel B, Arditi F, Reisner Y, Mozes E. Lupus manifestations in severe combined immunodeficient (SCID) mice and in human/mouse radiation chimeras. J Clin Immunol 2003; 23(2): p. 91-9.
69. Vladutiu, AO. The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases. Clin Exp Immunol 1993; 93(1): p. 1-8.